Edesa Biotech, Inc.
EDSA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.77
KIRA · Stoqly’s AI analyst, in plain words
- Edesa Biotech, Inc. lost $7.2M in fiscal 2025.
Market cap
—
P/E
—
Revenue
—
Net income
−$7.2M
Free cash flow
—
Operating margin
—
Edesa Biotech, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$7.2M
No. It lost money last year.
What Edesa Biotech, Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 12, 2025
- Legal name
- Edesa Biotech, Inc.
- CIK
- 0001540159
Edesa Biotech, Inc. · EDSA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | — | — | — | — |
| Net income | −$13.3M | −$17.5M | −$8.4M | −$6.2M | −$7.2M |
| Diluted EPS | −$1.10 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$13.7M | −$12.3M | −$6.6M | −$4.9M | −$7.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | — | — |
| Free cash flow | −$13.7M | −$12.3M | −$6.6M | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $7.8M | $7.1M | $5.4M | $1.0M | $10.8M |
| Shareholders' equity | $13.1M | $9.4M | $7.0M | $2.0M | $12.5M |
| Current ratio | 8.3x | 4.2x | 3.5x | 0.9x | 10.7x |
| Returns and quality | |||||
| Return on equity | −135.5% | −156.3% | −101.9% | −136.7% | −99.6% |
| Return on tangible equity | −125.0% | −246.8% | −172.0% | — | −68.6% |
| Altman Z'' | −3.1 | −14.6 | −18.8 | −61.6 | −2.6 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Edesa Biotech, Inc. · EDSA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.77 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001540159). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.